TABLE 1

Patient characteristics

Patients total/female28/13 (46)
Age, years63±15
Body mass index, kg·m−224.9±4.0
Pulmonary hypertension classification
 1 Pulmonary arterial hypertension15 (54)
  1.1 Idiopathic13 (46)
  1.4.1 Connective tissue disease associated1 (4)
  1.4.3 Portal hypertension1 (4)
 4 Chronic thromboembolic pulmonary hypertension13 (46)
  Inoperable6 (21)
  Post-endarterectomy4 (14)
  Potentially operable, patients yet undecided2 (7)
6-min walk distance, m558±95
NYHA functional class I, II, III9 (32), 14 (50), 5 (18)
N-terminal pro-brain natriuretic peptide, ng·L−1412±583
Maximal incremental ramp cycle exercise, W121±43
Maximal oxygen uptake, mL·min−1·kg−118.5±4
Resting arterial partial pressure of oxygen, kPa10.4±1.5
Pulmonary vascular resistance, WU5.8±2.8
Mean pulmonary arterial pressure, mmHg39±11
PH targeted therapy
 Endothelin receptor antagonist18 (64)
 Phosphodiesterase-5 inhibitor13 (46)
 Soluble guanylate cyclase stimulators10 (36)
 Prostacyclin receptor agonist or prostacyclin3 (11)
 Combination therapy8 (29)

Data are presented as n (%) or mean±sd. NYHA: New York Heart Association; PH: pulmonary hypertension.